Entheon Biomedical Corp.
Entheon Biomedical Corp. (ENBI.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
enbi.cn · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Entheon Biomedical Corp.You ENBI.CN | $1M | N/A | — | — |
 Captor Capital Corp. CPTR.CN | $1M | 0.28x | — | $2.21 |
 Copland Road Capital Corporation CRCC.CN | $1M | N/A | — | -$0.05 |
 Universal Ibogaine Inc. IBO.V | $2M | N/A | — | -$0.06 |
 Doseology Sciences Inc. MOOD.CN | $1M | N/A | — | -$0.10 |
 Ovation Science Inc. OVAT.CN | $0M | N/A | — | -$0.02 |
 Premier Health of America Inc. PHA.V | $1M | N/A | — | -$0.28 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Entheon Biomedical Corp. (ENBI.CN) measures how much investors pay for each dollar of the company's trailing earnings. ENBI.CN's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of —.
Frequently asked questions
ENBI.CN pe ratio · 6 questionsENBI.CN's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.10 and TTM EPS of —. Data sourced from Financial Modeling Prep via ENBI.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Entheon Biomedical Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10